Metabolic Dysfunction Associated Steatotic Liver Disease

Slide 1 · Metabolic dysfunction–associated steatotic liver disease

From metabolic disturbance to steatohepatitis, fibrosis and clinical consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Define MASLD and distinguish it from MASH and isolated steatosis.

Link insulin resistance and adipose dysfunction to hepatocellular lipid accumulation.

Recognize the key histologic features and characteristic fibrosis pattern.

Integrate morphology, clinical history and complications in diagnosis.

Slide 3 · Terminology identifies two different disease states

MASLD

Hepatic steatosis associated with cardiometabolic dysfunction, within the clinical exclusions.

MASH

The subset with steatohepatitic injury: Steatosis, lobular inflammation and hepatocyte ballooning.

Slide 4 · Steatotic liver disease is a morphologic spectrum

Hepatic steatosis

Steatohepatitic injury

Fibrotic remodeling

Cirrhosis / complications

This is a conceptual range, not an inevitable sequence for every patient.

Slide 5 · MASLD diagnosis requires clinical context

Hepatic fat

Evidence of steatosis in the liver

Metabolic setting

At least one cardiometabolic risk factor

Etiologic assessment

Alcohol exposure and competing causes evaluated

The defining clinical assessment is more than detecting a fatty liver.

Slide 6 · Steatosis alone is not etiologically specific

Hepatic fat may arise in several different liver diseases.

Hepatitis C, Wilson disease and medications among alternate causes to consider.

Alcohol history and potential coexisting insults must be assessed.

Do not label the cause from steatosis on imaging alone.

Slide 7 · The burden of MASLD is substantial

MASLD as the most common chronic liver disease in the United States.

Its projected prevalence in the source exceeds 30% of U.S. Adults by 2030.

Increasing MASLD is expected to increase the burden of MASH, cirrhosis and hepatocellular carcinoma.

The prevalence statement is a textbook projection, not a measured 2030 result.

Slide 8 · Cardiometabolic associations dominate the phenotype

Obesity

Expanded, metabolically dysfunctional adipose tissue

Insulin resistance

Central contributor to abnormal lipid flux

Type 2 diabetes

Frequent associated metabolic disorder

Hyperlipidemia

Associated dysregulation of lipid metabolism

Slide 9 · Insulin resistance does not fully determine severity

Shared background

Insulin resistance occurs in many affected individuals.

Variable outcome

Even with insulin resistance, disease severity varies substantially.

Slide 10 · Insulin resistance links adipose tissue to liver

Insulin resistance

Adipose metabolic dysfunction

Increased fatty-acid delivery

Hepatic triglyceride storage

Metabolic dysregulation alters the influx and handling of fatty acids.

Slide 11 · Visceral adipose tissue becomes dysfunctional

With insulin resistance, visceral fat expands and acquires abnormal endocrine functions.

The adipose compartment releases increased circulating free fatty acids.

Dysfunctional adipocytes also produce proinflammatory mediators.

Slide 12 · Circulating fatty acids feed hepatic steatosis

Visceral adipose tissue

Free fatty acids in circulation

Hepatocyte uptake

Triglyceride droplets

A key substrate supply route in MASLD pathogenesis.

Slide 13 · Reduced adiponectin promotes lipid accumulation

Adipose dysfunction

Lower adiponectin

Less muscle fatty-acid oxidation

Greater hepatic lipid availability

The source connects altered adipokine signaling with tissue lipid redistribution.

Slide 14 · Lipophagy normally helps clear stored lipid

Functional lipophagy

Selective autophagic processing of lipid droplets contributes to cellular lipid turnover.

Reduced lipophagy

Down-regulated lipid turnover can favor further hepatocyte fat accumulation.

Slide 15 · Steatosis reflects a net excess of stored lipid

1

More delivery

Free-fatty-acid influx into hepatocytes rises.

2

Altered disposal

Metabolic handling and lipophagy are impaired.

3

Net storage

Triglyceride accumulates in cytoplasmic droplets.

Slide 16 · Multiple inputs modify MASLD severity

Variable MASLD severity

Genetic variation

Diet composition

Intestinal microbiome

Obstructive sleep apnea

Other liver insults

These are contributory associations, not a single proven causal pathway.

Slide 17 · Dietary exposures may influence progression

High-fructose diets

Associated with increased MASLD-related fibrosis risk.

Dietary trans-fats

May contribute to hepatocellular injury.

Associations do not establish that either exposure independently explains every case.

Slide 18 · The microbiome is a plausible disease modifier

The source describes complex associations between intestinal microbes and MASLD.

Variation in intestinal products may contribute to between-patient differences.

An association with liver inflammation does not identify one specific responsible microbial species.

Slide 19 · Gut-derived endotoxin is linked to liver injury

Gut-derived endotoxin

Hepatic inflammatory signaling

Inflammation and hepatocyte injury

Potential fibrogenic response

An established association; The diagram does not imply a single sufficient cause.

Slide 20 · Sleep apnea may amplify chronic injury

Obstructive sleep apnea

Intermittent hypoxia

Additional hepatic stress

Association with progression

The hypoxia-mediated mechanism is suggested, not definitively established.

Slide 21 · An additional liver insult can accelerate fibrosis

MASLD can coexist with a second chronic liver disease.

Hemochromatosis as an example of a superimposed injury.

The combined insults may accelerate scarring and complicate attribution of liver damage.

Slide 22 · Adipose cytokines prime an inflammatory state

Dysfunctional adipocytes

Proinflammatory cytokines (TNF-α)

Inflammatory milieu

Heightened injury susceptibility

The metabolic and inflammatory arms of disease are interrelated.

Slide 23 · Oxidative stress links steatosis to injury

Fat-rich hepatocyte

Oxidative stress

Lipid peroxidation products

Cellular membrane damage

Fat storage alone and the response to lipid-associated injury are distinct processes.

Slide 24 · Lipid peroxidation targets cellular membranes

Mitochondrial membranes

Oxidative damage contributes to mitochondrial dysfunction and hepatocyte injury.

Plasma membrane

Peroxidation can impair cellular integrity and survival.

Slide 25 · Hepatocyte injury can culminate in cell death

Oxidative and inflammatory injury

Organelle / membrane damage

Apoptosis or necrosis

Inflammatory amplification

Different pathways of hepatocellular death can contribute to tissue damage.

Slide 26 · Kupffer-cell signaling connects injury to fibrosis

Hepatocyte injury

Kupffer-cell response

TNF-α and TGF-β signaling

Stellate-cell activation

The source identifies local cytokine release as a driver of scarring.

Slide 27 · Hepatic stellate cells deposit scar collagen

Activated stellate cells

Extracellular collagen deposition

Pericellular / sinusoidal fibrosis

Progressive architectural distortion

A cellular injury response becomes a sustained tissue-remodeling program.

Slide 28 · MASLD is a network, not a single-hit disease

Adipose dysfunction

Hepatic lipid storage

Oxidative stress

Inflammation

Stellate activation

Fibrosis

Causal model simplified from the source; Multiple modifiers affect each link.

Slide 29 · MASH is defined by a morphologic triad

Steatosis

Fat in ≥5% of hepatocytes

Lobular inflammation

Inflammatory cells within the parenchyma

Ballooning

Swollen hepatocytes showing injury

All three are required in the Robbins description of MASH.

Slide 30 · The steatosis threshold has a clear meaning

Robbins specifies steatosis involving at least 5% of hepatocytes for MASH morphology.

This is a histologic proportion of hepatocytes—not a percentage of liver volume or a blood biomarker.

Steatosis is necessary but not sufficient for MASH in the described triad.

Slide 31 · Fat droplets vary within hepatocytes

Schematic · not a histologic specimen

Mixed small and large cytoplasmic lipid droplets may appear; This is an editable schematic, not a tissue image.

Slide 32 · Ballooned hepatocytes signify cellular injury

Injured, enlarged hepatocyte

Schematic · not a histologic specimen

The swollen, pale-appearing hepatocyte is a component of the steatohepatitis diagnosis.

Slide 33 · Lobular inflammation completes the injury pattern

Schematic · not a histologic specimen

Inflammatory foci should be interpreted together with steatosis and ballooning.

Slide 34 · A triad-based reading prevents overdiagnosis

Is steatosis present in ≥5% of hepatocytes?

Interpretation

If absent: The Robbins MASH triad is not met.

Is lobular inflammation present?

Interpretation

If absent: Do not equate steatosis with steatohepatitis.

Are ballooned hepatocytes present?

Interpretation

If present with the above: MASH morphology is supported.

Slide 35 · Simple steatosis and MASH are not equivalent

Feature

Steatosis only

MASH

Hepatocellular fat

Present

Present

Lobular inflammation

Not part of isolated steatosis

Required by source

Ballooning

Not part of isolated steatosis

Required by source

Fibrosis risk

Variable

Higher risk of advanced fibrosis

Slide 36 · Alcoholic and metabolic steatohepatitis overlap

Both can exhibit steatosis, inflammation, hepatocyte ballooning and fibrosis.

That routine morphology cannot reliably determine the etiology.

Alcohol exposure, metabolic context and alternative causes must be evaluated together.

Slide 37 · Histologic differences are tendencies, not rules

Feature

Alcohol-associated pattern (on average)

MASH

Steatosis

Often less marked

Can be prominent

Ballooning / inflammation

Often more prominent

Part of required triad

Mallory hyaline / neutrophils

Often more prominent

May overlap

Cholestasis / central venous injury

More often emphasized

Less characteristic

Group-level trends; No one feature reliably assigns the cause.

Slide 38 · Etiology remains a clinicopathologic diagnosis

Clinical history

Characterize alcohol exposure and metabolic risks.

Pathology

Determine steatosis, injury and fibrosis pattern.

Exclusions

Consider viral, autoimmune and other metabolic causes.

Slide 39 · Early fibrosis favors a pericentral location

Central vein

Portal region

Schematic—not a photomicrograph. Early scarring arises near the central vein and surrounding hepatocytes.

Slide 40 · Pericellular fibrosis forms a chicken-wire pattern

Central vein

Portal region

Schematic—not a photomicrograph. Pericellular collagen outlines hepatocytes; Trichrome can aid detection.

Slide 41 · Fibrosis spreads beyond the pericentral region

Pericellular fibrosis

Periportal fibrosis

Bridging fibrosis

Cirrhosis

A usual sequence; Individual patterns and rates vary.

Slide 42 · Pericentral and portal fibrosis are distinct

Pericentral pattern

Fine pericellular collagen near central veins is typical in adult MASH.

Portal pattern

Portal-area fibrosis is emphasized in many pediatric cases.

Slide 43 · Cirrhosis can obscure the original steatohepatitis

Established cirrhosis may persist after obvious fat accumulation diminishes.

Ballooned hepatocytes can also be reduced or absent in the cirrhotic liver.

The absence of current steatosis therefore does not exclude prior MASH.

Slide 44 · “Burned-out” MASH is a diagnostic pitfall

Advanced cirrhotic liver

Little visible steatosis or ballooning

Review metabolic risk factors

Exclude alternative cirrhosis causes

The source discusses this pathway among cases labeled cryptogenic cirrhosis.

Slide 45 · Pediatric MASLD is morphologically different

Morphologic feature

Typical adult pattern

Pediatric pattern

Steatosis

Variable distribution

Often more diffuse

Fibrosis

Often central / pericellular initially

Often portal

Ballooning

Characteristic for MASH triad

May be absent

Adult diagnostic expectations should not be imposed without qualification on children.

Slide 46 · Clinical trajectories vary substantially

Asymptomatic steatosis

MASH in a subset

Progressive fibrosis in a subset

Cirrhosis / carcinoma in some

The schematic is a range of potential outcomes, not a deterministic patient timeline.

Slide 47 · Isolated steatosis is frequently silent

Individuals with steatosis alone are generally asymptomatic.

Fat accumulation may be detected incidentally on imaging.

Absence of symptoms does not establish absence of histologic injury.

Slide 48 · Presentation often reflects metabolic comorbidity

Clinical encounters may be driven by insulin resistance or type 2 diabetes.

Obesity and lipid abnormalities commonly coexist.

The liver abnormality may be secondary in the clinical presentation yet prognostically important.

Slide 49 · Symptoms, when present, are often nonspecific

Fatigue

May occur without severe or distinctive liver symptoms.

Right upper abdominal discomfort

May reflect hepatic enlargement.

Neither symptom identifies MASH or grades fibrosis.

Slide 50 · Aminotransferase elevation does not define MASH

AST and ALT are elevated in many patients with MASH.

Patients may remain asymptomatic despite abnormal enzymes.

Biochemistry alone cannot establish the requisite histologic triad or stage fibrosis.

Slide 51 · Imaging reveals fat but not the full injury pattern

Imaging

Can show hepatic fat accumulation.

Liver biopsy

Characterizes steatohepatitis and contributes to fibrosis assessment.

The Robbins source specifically requires biopsy for definitive MASH diagnosis.

Slide 52 · Histology answers questions imaging cannot

Inflammation

Is lobular inflammatory injury present?

Ballooning

Are damaged, enlarged hepatocytes demonstrable?

Fibrosis

How extensive is scar deposition and what pattern is present?

Slide 53 · The differential diagnosis must remain open

Viral hepatitides can coexist with or mimic elements of chronic liver injury.

Autoimmune liver disease and metabolic conditions require consideration.

Medication and alcohol histories help identify alternative or combined etiologies.

Slide 54 · Mixed etiologies require explicit evaluation

Evidence of steatosis

Assess metabolic risk and alcohol

Review viral, drug and metabolic insults

Integrate biopsy when appropriate

A patient can have more than one contributor to liver injury.

Slide 55 · An integrated diagnostic synthesis has four layers

Metabolic milieu

Obesity, insulin resistance, type 2 diabetes, lipids

Hepatic phenotype

Steatosis versus steatohepatitic injury

Fibrotic burden

Pericellular, periportal, bridging or cirrhotic

Competing insults

Alcohol, viral, drug-induced, inherited disease

Slide 56 · Fibrosis assessment changes clinical priorities

MASH is associated with increased risk of advanced fibrotic disease.

Assessment of the extent of fibrosis for management.

Scar progression—not merely the presence of fat—drives major liver-related complications.

Slide 57 · Cardiovascular disease is a major clinical outcome

Metabolic dysfunction

Shared cardiovascular risk milieu

Cardiovascular disease

Important cause of death in MASH

Clinical risk extends beyond the liver.

Slide 58 · Progressive liver injury can decompensate

Persistent hepatocellular injury

Progressive fibrosis

Cirrhosis

Potential decompensated cirrhosis

Decompensated cirrhosis among serious complications.

Slide 59 · MASH increases hepatocellular carcinoma risk

MASH is associated with greater hepatocellular carcinoma risk.

Advanced chronic liver disease is one pathway to liver-related morbidity.

Cancer risk must be interpreted alongside other underlying metabolic and hepatic conditions.

Slide 60 · Management targets the underlying metabolic disorder

Obesity

Correct excess adiposity and associated metabolic dysfunction.

Hyperlipidemia

Address the abnormal lipid-metabolic milieu.

Insulin resistance

Treat the metabolic condition sustaining hepatic injury.

Slide 61 · Lifestyle change can improve histologic injury

Weight reduction

Dietary modification

Exercise

Potential histologic improvement

Lifestyle interventions can potentially reverse MASH abnormalities; No unverified effect sizes are presented.

Slide 62 · Therapeutic claims must match the source

The source prioritizes reducing hepatic injury and preventing or reversing fibrosis.

It notes active pharmacologic research but supplies no drug-specific trial results.

No current drug approvals, efficacy rates or treatment thresholds are inferred from this source extract.

Slide 63 · Case 1 · Fatty liver discovered incidentally

Clinical vignette

An asymptomatic adult with obesity and type 2 diabetes has hepatic steatosis on imaging.

AST and ALT are not provided; No biopsy has been performed.

Question: What can be concluded—and what remains unproven?

Slide 64 · Case 1 · Separate steatosis from steatohepatitis

Supported

Hepatic fat plus relevant metabolic risk.

Not yet established

Ballooning, lobular inflammation and fibrosis stage.

Next interpretive task

Evaluate alcohol and competing hepatic causes.

Slide 65 · Case 2 · Histologic features converge

Clinical vignette

A liver biopsy shows steatosis in ≥5% of hepatocytes, lobular inflammation and ballooning.

Pericellular collagen is highlighted by trichrome.

Question: What does pathology establish, and what does it not?

Slide 66 · Case 2 · Morphology requires etiologic correlation

Pathology establishes

Steatohepatitis and pericellular fibrotic change.

Clinical history establishes

Exposure and metabolic setting relevant to etiology.

Avoid

Calling MASH solely from a microscopic pattern.

Slide 67 · Case 3 · Cirrhosis with little current steatosis

Clinical vignette

A patient has established cirrhosis and longstanding type 2 diabetes and obesity.

Current biopsy shows little fat and few ballooned hepatocytes.

Question: Does the morphology rule out a prior MASH pathway?

Slide 68 · Case 3 · Recognize burned-out disease carefully

Established cirrhosis

Metabolic risk history

Reduced steatosis is not exclusionary

Evaluate other etiologies

Retrospective attribution remains clinicopathologic, not based on a single absent lesion.

Slide 69 · Synthesis · The causal sequence to remember

Metabolic dysregulation

Hepatic lipid accumulation

Oxidative / inflammatory injury

MASH morphology

Stellate-cell collagen

Fibrosis and outcomes

Genetic, dietary, intestinal and comorbid factors modify progression.

Slide 70 · The diagnostic synthesis in one frame

Fat

Recognize and assess the hepatic steatosis.

Injury

Find ballooning and lobular inflammation.

Scar

Determine fibrosis distribution and extent.

Cause

Use metabolic, alcohol and alternative etiologic history.

Slide 71 · Source and interpretation notes

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 18, “Liver and Gallbladder,” pp. 766–771.

Primary source section: “Metabolic Dysfunction–Associated Steatotic Liver Disease,” beginning p. 769.

Morphologic schematics are original editable PowerPoint drawings—not specimens or reproductions of textbook figures.

The extracted source contains no reusable figure files. No external treatment algorithms were added.